{
    "title": "Loxo signs lucrative cancer drug deal with Bayer, but shares fall",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-5081731/Bayer-agrees-cancer-drug-deal-Loxo-worth-1-55-bln.html",
    "date": "2017-11-14",
    "keywords": [
        "deal",
        "cancer",
        "bayer",
        "loxo",
        "larotrectinib",
        "oncology",
        "tumor",
        "company",
        "percent",
        "defect",
        "drug",
        "loxo195",
        "disease",
        "analyst",
        "development",
        "bill",
        "berkrot",
        "tamara",
        "tuesday",
        "collaboration",
        "agreement",
        "promising",
        "germanys",
        "ag",
        "likelihood",
        "takeover",
        "excitement",
        "meeting",
        "shrinkage",
        "dozen",
        "entry",
        "field",
        "organ",
        "news",
        "number",
        "term",
        "sale",
        "launch",
        "asset",
        "dane",
        "leone",
        "stage",
        "cowen",
        "schmidt",
        "upfront",
        "milestone",
        "belong",
        "class",
        "trk",
        "cell",
        "growth",
        "response",
        "mutation",
        "driver",
        "regardless",
        "type",
        "lacaze",
        "revenue",
        "decline",
        "bestselling",
        "xarelto",
        "patent",
        "protection",
        "approval",
        "year",
        "percentage",
        "exus",
        "reporting",
        "burger",
        "frankfurt",
        "editing",
        "david",
        "gregorio",
        "hugh",
        "lawson"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}